Anika Therapeutics, Inc.
$197.18M- Market cap
- $278.50M
- Debt
- +-$149.00K
- Cash
- −$81.17M
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: ANIK stock price near parity vs AZZ $20.81 current versus $21.50 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AZZ's multiple
Implied fair value · at ANIK's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · AZZ FY 2026 (ended Feb 28, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
Capital structure 90% equity / 10% debt · EV / Revenue 2.84x · EV / EBITDA 7.69x
AZZ carries the larger enterprise value at $4.68B against $197.18M; ANIK trades on the lower EV / Revenue multiple (1.75x vs 2.84x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Anika Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
AZZ Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.00x
0.36x
Net debt / EBITDA
Leverage against operating earnings
34.65x
0.78x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$705.00K
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ZIMMER BIOMET HOLDINGS, INC.
ANIK vs ZBH
STRYKER CORP
ANIK vs SYK
BECTON DICKINSON & CO
ANIK vs BDX
INTEGRA LIFESCIENCES HOLDINGS CORP
ANIK vs IART
VALMONT INDUSTRIES INC
ANIK vs VMI
SMITH A O CORP
ANIK vs AOS
PPG INDUSTRIES INC
ANIK vs PPG
Fabrinet
ANIK vs FN
WORTHINGTON ENTERPRISES, INC.
ANIK vs WOR
STEEL DYNAMICS INC
ANIK vs STLD
-$149.00K
$477.74M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.